Proton Nuclear Magnetic Resonance Spectroscopic Imaging Compared With Fludeoxyglucose F 18 Positron Emission Tomography Scanning in Determining Biologic or Metabolic Tumor Activity in Young Patients With Brain Tumors
| Status: | Archived |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
A Comparative Study of Pediatric CNS Tumor Activity as Assessed by [18F-]-FDG PET Imaging and Proton Magnetic Resonance Spectroscopic Imaging (1H-MRSI)
RATIONALE: Diagnostic procedures, such as proton nuclear magnetic resonance spectroscopic
imaging and fludeoxyglucose F 18 positron emission tomography may improve the ability to
detect the extent of cancer in young patients who have brain tumors.
PURPOSE: This clinical trial is studying how well proton nuclear magnetic resonance
spectroscopic imaging works compared to fludeoxyglucose F 18 positron emission tomography in
finding tumor activity and the extent of cancer in young patients with brain tumors.
OBJECTIVES:
Primary
- Compare proton nuclear magnetic resonance spectroscopic imaging (^1H-MRSI) vs
fludeoxyglucose F 18 positron emission tomography (FDG PET) scanning in determining
biologic or metabolic activity in pediatric patients with brain tumors.
Secondary
- Correlate results of these imaging techniques with standard MRI readings and outcome in
these patients.
- Utilize these imaging techniques and various magnetic resonance sequences to evaluate
changes over time in primary brain tumors as a result of the natural history of the
lesion or therapeutic effects in these patients.
OUTLINE: Patients undergo standard MRI evaluation and proton nuclear magnetic resonance
spectroscopic imaging (^1H-MRSI). Within 2 weeks after ^1H-MRSI, patients then undergo
fludeoxyglucose F 18 (FDG) positron emission tomography (PET) imaging. Patients may undergo
repeat MRI and ^1H-MRSI scans every few months as needed. Patients undergo no more than 1
FDG PET scan per year.
Patients remain on this study for up to 2 years.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
We found this trial at
1
site
National Cancer Institute (NCI) The National Cancer Institute (NCI) is part of the National Institutes...
Click here to add this to my saved trials
